#1 Clinical Trials Search in Europe

Immunoglobulins, Normal Human

This article explores recent clinical trials investigating the use of Immunoglobulins, Normal Human for treating different medical conditions. These trials aim to evaluate the safety, effectiveness, and potential applications of this treatment in various patient populations, including children with generalized myasthenia gravis, pregnant women at risk of fetal and neonatal alloimmune thrombocytopenia, and adults with immune thrombocytopenia experiencing moderate to severe bleeding.

Table of Contents

What are Immunoglobulins?

Immunoglobulins, also known as antibodies, are proteins produced by the immune system to fight off infections and diseases. Normal human immunoglobulins are derived from the blood plasma of healthy donors and contain a wide variety of antibodies that can help boost the immune system of patients with various medical conditions[1].

Medical Conditions Treated

Normal human immunoglobulins are used to treat several medical conditions, including:

  • Generalized Myasthenia Gravis (gMG): A rare autoimmune disorder that causes muscle weakness and fatigue[2].
  • Immune Thrombocytopenia (ITP): A condition where the immune system mistakenly attacks and destroys platelets, leading to easy bruising and bleeding[3].
  • Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT): A rare condition where a pregnant woman’s immune system attacks her fetus’s or newborn’s platelets[4].
  • Hypophosphatasia: A rare inherited disorder that affects bone and tooth development[5].

Administration and Dosage

Normal human immunoglobulins are typically administered intravenously (through a vein). The dosage and frequency of treatment can vary depending on the specific medical condition and individual patient needs. For example:

  • In the treatment of immune thrombocytopenia, patients may receive 1g/kg of immunoglobulins on days 1 and 2 of treatment[3].
  • For fetal and neonatal alloimmune thrombocytopenia, pregnant women may receive immunoglobulin treatments throughout their pregnancy[4].

Effectiveness and Safety

Clinical trials have shown that normal human immunoglobulins can be effective in treating various conditions. For instance, in patients with generalized myasthenia gravis, immunoglobulins have been found to improve muscle strength and reduce symptoms[2].

The safety profile of normal human immunoglobulins is generally good, but as with any medical treatment, there can be side effects and risks. Doctors carefully monitor patients during and after treatment to ensure safety and effectiveness[3].

Potential Side Effects

While normal human immunoglobulins are generally well-tolerated, some patients may experience side effects. These can include:

  • Headache
  • Nausea
  • Fever
  • Chills
  • Fatigue
  • Allergic reactions (in rare cases)

It’s important to discuss any side effects with your healthcare provider[3].

Ongoing Research

Researchers continue to study the use of normal human immunoglobulins in various medical conditions. Current clinical trials are investigating:

  • The effectiveness of immunoglobulins in children with generalized myasthenia gravis[2].
  • The use of immunoglobulins in combination with other treatments for immune thrombocytopenia[3].
  • The potential of immunoglobulins to prevent complications in pregnancies at risk of fetal and neonatal alloimmune thrombocytopenia[4].

These ongoing studies aim to improve our understanding of how immunoglobulins work and how they can be used most effectively to help patients with various medical conditions.

Trial Focus Patient Population Key Objectives Treatment Regimen
Generalized Myasthenia Gravis (gMG) Children aged 2 to <18 years Assess safety, tolerability, and effectiveness of rozanolixizumab Subcutaneous rozanolixizumab administration
Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) Pregnant women at risk of FNAIT Compare efficacy of nipocalimab vs. IVIg Nipocalimab or IVIg (dosing not specified)
Immune Thrombocytopenia (ITP) Adults with ITP and moderate to severe bleeding Compare dexamethasone vs. IVIg + prednisone Dexamethasone 40 mg (days 1-4) or IVIg 1g/kg (days 1-2) + prednisone
Hypophosphatasia (HPP) Patients ≥2 years with immune-mediated loss of effectiveness to asfotase alfa Evaluate immunosuppressive therapies to mitigate loss of effectiveness Various immunosuppressive regimens (not fully specified)

FAQ

  • What is Immunoglobulins, Normal Human? Immunoglobulins, Normal Human is a blood-derived product containing antibodies that help fight infections and modulate the immune system. It is typically administered intravenously (IV) or subcutaneously (SC) to treat various immune-related conditions.
  • What medical conditions are being studied in these clinical trials? The clinical trials are investigating the use of Immunoglobulins, Normal Human for conditions such as generalized myasthenia gravis in children, fetal and neonatal alloimmune thrombocytopenia in pregnant women, and immune thrombocytopenia in adults with moderate to severe bleeding.
  • How is Immunoglobulins, Normal Human administered in these trials? In the trials, Immunoglobulins, Normal Human is typically administered intravenously (IV). The dosage and frequency of administration may vary depending on the specific trial and medical condition being studied.
  • Are there any side effects associated with Immunoglobulins, Normal Human? While the trials aim to assess the safety of the treatment, common side effects of Immunoglobulins, Normal Human may include headache, fever, and infusion site reactions. Serious side effects are rare but can occur. The trials will closely monitor participants for any adverse events.
  • How long do these clinical trials last? The duration of the clinical trials varies. Some trials may last for several weeks, while others may extend up to 18 weeks or even longer, depending on the specific study design and objectives.

Ongoing Clinical Trials on Immunoglobulins, Normal Human

  • Study on the Safety and Effectiveness of Rozanolixizumab in Children with Generalized Myasthenia Gravis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Poland

  • Study on the Safety and Effectiveness of Rozanolixizumab and Immunoglobulins in Children with Generalized Myasthenia Gravis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Poland

Glossary

  • Generalized Myasthenia Gravis (gMG): A chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue, affecting multiple muscle groups throughout the body.
  • Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT): A condition where a pregnant woman's immune system produces antibodies against her fetus's platelets, potentially leading to low platelet counts and bleeding risks in the fetus or newborn.
  • Immune Thrombocytopenia (ITP): A blood disorder characterized by a low platelet count due to the immune system mistakenly attacking and destroying platelets, which can lead to easy bruising and bleeding.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Antidrug Antibodies (ADAs): Antibodies produced by the immune system in response to a therapeutic drug, which may affect the drug's effectiveness or cause adverse reactions.
  • Immunosuppressive Therapy (IST): Treatment that suppresses or reduces the strength of the body's immune system, often used to prevent rejection of transplanted organs or to treat autoimmune diseases.
  • Enzyme-Replacement Therapy (ERT): A medical treatment that replaces an enzyme the body is lacking or not producing enough of due to a genetic disorder.
  • Intravenous Immunoglobulin (IVIg): A blood product containing pooled immunoglobulin G (IgG) antibodies from many blood donors, administered intravenously to treat various immune-related conditions.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-rozanolixizumab-in-children-with-generalized-myasthenia-gravis/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-rozanolixizumab-and-immunoglobulins-in-children-with-generalized-myasthenia-gravis/
  3. http://clinicaltrials.eu/trial/study-on-dexamethasone-prednisolone-and-immunoglobulin-for-adults-with-immune-thrombocytopenia-and-moderate-to-severe-bleeding/
  4. http://clinicaltrials.eu/trial/study-of-nipocalimab-or-ivig-for-pregnant-women-at-risk-of-fetal-and-neonatal-alloimmune-thrombocytopenia-fnait/
  5. http://clinicaltrials.eu/trial/study-on-immunosuppressive-therapies-with-asfotase-alfa-for-patients-with-hypophosphatasia-experiencing-reduced-treatment-effectiveness/